Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05756907 · ClinicalTrials.gov registry record · Phase 1
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
A Phase 1 study, sponsored by Sonnet BioTherapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT05756907 is a Phase 1 study that was terminated before completion, run by Sonnet BioTherapeutics. The registered enrollment target is 40 participants.
The verdict
NCT05756907, a Phase 1 study, was terminated before completion, sponsored by Sonnet BioTherapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a Phase 1b/2a, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 in combination with atezolizumab administered to patients with advanced solid tumors (Part 1) and patients with Platinum-resistant Ovarian Cancer (Part 2)
Interventions
- BIOLOGICAL SON-1010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-09-15 |
| Est. Completion | 2026-01-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05756907
The ClinicalTrials.gov registry entry for NCT05756907 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sonnet BioTherapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SON-1010 is the first listed.
NCT05756907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05756907 about?
NCT05756907 is a clinical study titled "Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer". This is a Phase 1b/2a, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 in combination with atezolizumab administered to patients with advanced solid tumors (Part 1) and patients with Platinum-resistant Ovarian Cancer (Part 2)
What is the current status of trial NCT05756907?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-09-15. Estimated completion is 2026-01-08.
What interventions are being tested in trial NCT05756907?
The interventions under investigation include: SON-1010 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05756907?
This trial is sponsored by Sonnet BioTherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.